Skip to content

effect of dexmedetomidin on post CABG atrial fibrillation

comparison of dexmedetomidin and placebo on postoperative atrial fibrillation control in patients undergoing coronary artery bypass graft surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017021914359N4
Enrollment
110
Registered
2017-03-20
Start date
2017-03-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation. Atrial fibrillation and flutter

Interventions

Intervention 1: Intervention group: An infusion of dexmedetomidine after induction, as much as 0.3-0.5 µgr/kg per hour for 24 hours. Intervention 2: Control group: infusion of normal salin after induc
Treatment - Drugs
Intervention group: An infusion of dexmedetomidine after induction, as much as 0.3-0.5 µgr/kg per hour for 24 hours
Control group: infusion of normal salin after induction, as much as 0.3-0.5 µgr/kg per hour for 24 hours.

Sponsors

Vice Chancellor for research of Guilan university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: elective CABG surgery; 35 to 65 year old patients; 3 or more coronary artery stenosis; EF>45%; normal sinus rhythm; normal liver and kidney function. Exclusion criteria: pre-operative diagnosed bradycardia; HR<50; pregnancy; thyroid dysfunction; uncontrolled diabetes; history of corticosteroids use; addiction.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Morphin requirement. Timepoint: within 48 hours after ICU admission. Method of measurement: Visual analogue score.;Onset of atrial fibrillation. Timepoint: Within 24 hours of ICU admission. Method of measurement: ECG 12 lead whenever seen arrhythmia in monitoring and 24 hours monitoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Vali Imantalab

Heshmat hospital

arcguilan1392@gmail.com; vimantalab@gums.ac.ir+98 911 131 6138

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026